Scott E. Strome
Dr. Strome is a visionary physician–scientist with nearly three decades of experience developing immune-based protein therapeutics for cancer and autoimmunity. A fellowship-trained head and neck surgical oncologist, his work has helped propel four drug platforms into clinical trials - anti-PD-L1, “Trojan” peptide cancer vaccines, and two recombinant Fc multimers for autoimmune diseases. He has led pioneering translational research laboratories, mentoring PhD students, postdoctoral fellows, and a wide range of faculty. To date, he has published 132 peer-reviewed papers (18,912 citations; h-index 61, per Google Scholar, March 2025), many focused-on immunology and drug development.
Bio
Dr. Strome’s deep administrative experience in the academic and biotechnology arenas complements his research acumen. He is the cofounder and founding scientist of Gliknik Inc., which has advanced three drugs into clinical trials. He has also chaired three departments at the University of Maryland School of medicine (UMSOM) (two on an interim basis), co-founded and co-directed the Tumor Immunology Program at the Marlene and Stewart Greenbaum NCI-designated Cancer Center at the UMSOM, served on the Recombinant DNA Advisory Committee, and most recently acted as Executive Dean and Vice Chancellor for Clinical Affairs at the University of Tennessee Health Science Center College of Medicine (2018–August 2023).
As CEO of INTcRON, Dr. Strome draws on his proven record in biologics development, translational immunology, and team building to drive novel therapies into the clinic. His extensive background in bench-to-bedside research, successful drug development, and organizational leadership underscores his ability to deliver meaningful patient outcomes—and strong returns for investors.